Calcium-dependent Activation of Nuclear Factor Regulated by Interleukin 3/Adenovirus E4 Promoter-binding Protein Gene Expression by Calcineurin/Nuclear Factor of Activated T Cells and Calcium/Calmodulin-dependent Protein Kinase Signaling*

Yuhei Nishimura and Toshio TanakaDagger

From the Department of Molecular and Cellular Pharmacology, Mie University School of Medicine, Edobashi, Tsu, Mie 514-8507, Japan

Received for publication, November 14, 2000, and in revised form, March 20, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

An increase in the intracellular Ca2+ concentration controls a diverse range of cell functions, including gene expression, apoptosis, adhesion, motility, and proliferation. We have investigated Ca2+ regulation of gene expression in rat aortic smooth muscle cells. We found that the expression of nuclear factor regulated by interleukin 3 (NFIL3)/adenovirus E4 promoter-binding protein (E4BP4)/basic region/leucine zipper (bZIP) type of a transcription factor that has a very important function in cell survival, was activated by thapsigargin (TG). This activation was inhibited by chelation of extra- or intracellular Ca2+, suggesting that the induction by TG was dependent on the elevation of [Ca2+]i. Specific inhibition of calcineurin or calcium/calmodulin-dependent protein kinase (CaM kinase) by chemical means impaired the TG-induced NFIL3/E4BP4 expression. Expression of dominant negative forms of calcineurin or nuclear factor of activated T cells (NFAT) inhibited the induction of NFIL3/E4BP4 mRNA by TG. These results suggest that intracellular Ca2+ plays a critical role in regulating gene expression of NFIL3/E4BP4 by calcineurin/NFAT and CaM kinase signaling in vascular smooth muscle cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Calcium signals regulate numerous cell functions, including gene expression, some forms of programmed cell death, motility, secretion, proliferation, and cell survival (1). ([Ca2+]i can be raised experimentally by a number of agents, including the microsomal calcium ATPase inhibitor TG1 (1, 2). We investigated the regulation of gene expression in rat aortic smooth muscle cells (RASMC) exposed to TG by utilizing the fluorescent differential display technique (3). We compared the complementary DNA fragments from differentially expressed RASMC mRNAs following 3 h treatment with either vehicle or 100 nM TG. This analysis resulted in the identification of the rat homologue of NFIL3/E4BP4 as a TG-inducible gene.

NFIL3/E4BP4 was originally isolated as a novel member of the bZIP family of DNA-binding proteins that displays an unusual DNA binding specificity which overlaps that of the activating transcription factor family and cAMP response element-binding protein (4). NFIL3/E4BP4 repressed promoter activity and this repression was mediated through the cAMP response element/activating transcription factor-like site (5). NFIL3/E4BP4 might play a role in the glucocorticoid repression of several genes, because NFIL3/E4BP4 was induced by the synthetic glucocorticoid dexamethasone (6). Moreover, NFIL3/E4BP4 repressed the stimulating activity of box alpha , which is an essential element that positively regulates the transcription of human hepatitis B virus genes (7). The potent suppression of box alpha  activity by NFIL3/E4BP4 may contribute to the silencing of hepatitis B virus gene expression (7).

NFIL3/E4BP4 also plays an important role in the expression of IL-3 in T cells (8). In mouse pro-B cell lines, NFIL3/E4BP4 was also regulated as a delayed-early IL-3 responsive gene, requiring de novo protein synthesis (9). In the absence of IL-3, enforced expression of human NFIL3/E4BP4 promoted the survival but not the growth of IL-3-dependent pro-B cells, indicating that induction of NFIL3/E4BP4 is one of the mechanisms through which IL-3 suppresses apoptosis (9).

Recently, it has been found that the expression of NFIL3/E4BP4 was regulated by oncogenic Ras mutant proteins through both the Raf-mitogen-activated protein kinase and the phosphatidylinositol 3-kinase pathways in murine Pro-B lymphocytes (10). Ras-NFIL3/E4BP4 pathways may be common targets for a variety of oncogenes (10).

In this paper, we describe the cloning and calcium regulation of expression of rat NFIL3/E4BP4 in RASMC. We show that TG induced rat NFIL3/E4BP4 gene expression by activating the calcineurin/NFAT and by CaM kinase signaling. Thus, calcium signaling may be critical for the regulation of NFIL3/E4BP4 through calcineurin/NFAT and CaM kinase signaling in vascular smooth muscle cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- Thapsigargin, calcium ionophore A23187, phorbol 12-myristate 13-acetate (PMA), actinomycin D, and cycloheximide were purchased from Sigma. Cyclosporin A, FK506, KN-93, and PD98059 were purchased from CalBiochem. KN-92 was purchased from SeikagakuKogyo Co. Tokyo, Japan.

Cloning of Rat NFIL3/E4BP4 cDNA-- For cloning the 3'-half of the rat NFIL3/E4BP4 cDNA, we performed a rapid amplification of cDNA ends (RACE) (11). The 3'-half of the full-length cDNA was obtained using the primers 5'-TTACCGCACAAGCTCCGGATTAAAG-3' and 5'-CCATCCTAATACGACTCACTATAGGGC-3' for the first RACE and 5'-GCAGATGCGCTAGCCAAAAGACATT-3' and 5'-ACTCACTATAGGGCTCGAGCGGC-3' for the second RACE. A rat heart Marathon cDNA amplification kit (CLONTECH) was used for the template. Unfortunately, we could not obtain the 5'-half of the full-length cDNA by RACE, and so we performed polymerase chain reactions (PCR) using a degenerate primer. The 5'-half of the full-length cDNA was obtained by using the primers 5'-AAGGMKYCTGACRGATTTAYCC-3' and 5'-ATGTTCGTCACCTGCACCGAGAAAG-3'. The PCR products were sequenced using an automated DNA sequencer (Applied Biosystems).

Northern Blotting Analysis-- Northern blotting analysis was carried out using Rat Multiple Tissue Northern blots (CLONTECH). 32P-Random prime-labeled fragment of the rat NFIL3/E4BP4 cDNA (nucleotides 1093-1701) probe was synthesized with Strip-EZ DNA (Ambion). The heat-denatured cDNA probe was added at 2 × 106 cpm/ml to ExpressHyb hybridization solution (CLONTECH). The probe was hybridized to the RNA blots for 1 h at 65 °C. The membrane was washed according to the manufacturer's protocol and exposed to x-ray film at -80 °C. The filter was re-probed with 32P-random prime-labeled fragment of the rat beta -actin cDNA to ensure approximately equally loading of RNA samples.

Plasmid Constructs-- The dominant negative human calcineurin (12) and NFAT (13) were constructed as described previously. Briefly, the human calcineurin A2 coding region (aa 1-407) and human NFAT3 coding region (aa 1-160) were obtained by PCR using a human heart Marathon cDNA amplification kit (CLONTECH) as template. The PCR products of calcineurin A2 and NFAT3 were subcloned into the EcoRI and NotI sites of the plasmid vector pcDNA.3.1/His (Invitrogen). The pcDNA-Luc expression vector was prepared by subcloning the luciferase coding region into the EcoRI and NotI sites of pcDNA.3.1/His expression vector. The sequence of all PCR-derived constructs was confirmed by automated DNA sequencing.

Site-directed Mutagenesis-- In vitro directed mutagenesis was performed by using the commonly used overlap-extension method (14). Synthetic oligonucleotide primers containing the desired mutations and complementary to opposite strands of the corresponding plasmid constructs were extended by using KOD-plus DNA polymerase (TOYOBO), generating mutated plasmids. Primers used were pcD-CNA2 (H101Q) mutated primer: 5'-TGTGTGGTGACATCCAgGGCCAATTTTTTG-3', pcD-CNA2 (H290Q) mutated primer: 5'-TTATTAGAGCTCAgGAAGCTCAAGATGCAG-3', pcD-NFAT3 (AxIxIA) mutated primer: 5'- GAGTGTgCCAGCATCCGCATCgCCTCCATC-3', and pcD-NFAT3 (AxAxIA) mutated primer: 5'- GAGTGTgCCAGCgcCCGCATCgCCTCCATC-3'. Lowercase letters in the sequence of primers indicated mutated positions. Mutagenesis of more than one site was done by subsequent mutation of the corresponding previously mutated construct. The nucleotide sequence of the constructs was confirmed by automatic DNA sequencing.

Cell Culture and DNA Transfection-- Rat aortic smooth muscle cells (A7r5 cells, CRL-1444) were obtained from the American Type and Culture Collection. A7r5 cells were grown in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (Life Technologies), 25 µg/ml streptomycin, and 25 units/ml penicillin (Life Technologies). Cultures were maintained at 37 °C in a humidified atmosphere of 95% air, 5% CO2. All experiments were conducted on cells at passages 2-5. Quiescent A7r5 cells were obtained by incubation of preconfluent cell cultures in Dulbecco's modified Eagle's medium supplemented with 0.5% fetal calf serum for 48 h after which drugs were added to the culture medium.

For transient transfection experiments, A7r5 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum in a 25-cm2 flask. Cells in the logarithmic growth phase were transfected in 2 ml of Dulbecco's modified Eagle's medium plus 0.5% fetal calf serum using 1 µg of the indicated plasmid, 1 µg of pcDNA-Luc, and 8 µl of Tfx-50 (Promega). Transfected A7r5 cells were incubated for 48 h and exposed to vehicle or 30 nM TG for 3 h.

RNA Isolation and cDNA Synthesis-- Total RNAs were isolated and purified by using ISOGEN (Nippon Gene) reagent according to the manufacturer's instructions. Total RNAs (0.5-1 µg) were converted to cDNA using oligo(dT)11-18 primer (Amersham Pharmacia Biotech) and Superscript II reverse transcriptase (Life Technologies) according to the manufacturer's protocol. After synthesis of cDNA, the reaction mixtures were diluted 5-fold by addition of TE (10 mM Tris, 1 mM EDTA, pH 8.0) for real time RT-PCR.

Real Time RT-PCR-- To monitor mRNA expression, we used real time RT-PCR analysis. This novel approach has been described previously (15, 16). For rat NFIL3 real time RT-PCR analysis, the following primers were used; rNFIL3U, 5'-AAGGGCCCCATCCATTCT-3'; and rNFIL3L, 5'-TGAGGGACCAATCTTGAA-3'. The fluorescent probe for the real time RT-PCR was rNFIL3P, 5'-AAAGCCAAGGCCATGCAGGTCAA-3'. The GAPDH primers and probe (TaqMan GAPDH detection reagents) were purchased from Applied Biosystems. For luciferase real time RT-PCR analysis, the following primers were used: LucU, 5'- TGTCGCTCTGCCTCATAGAACTG-3'; and LucL, 5'- CAGCAGCGCACTTTGAATCTTG-3'. The fluorescent probe for the real time PCR was LucP: 5'- CATTCCGGATACTGCGATTTTAAGTGT-3'. The RT-PCR reaction and the resulting relative increase in reporter fluorescent dye emission were monitored in real time by the 7700 sequence detection program (Applied Biosystems). Conditions were as follows: 1 cycle at 50 °C for 10 min, 1 cycle at 94 °C for 15 min, 40 cycles at 94 °C for 30 s, 60 °C for 1 min.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of Rat NFIL3/E4BP4-- To study the effect of elevated intracellular Ca2+ concentration on gene expression, RASMC were treated with 100 nM TG for 3 h. RNA was isolated from non-stimulated or TG-stimulated RASMC and subjected to a fluorescent differential display (3). A highly induced band was reproducibly displayed when the primer pair G(T)15A and 5'-GAAACGGGTG-3' was used. This band was cut from the gel, re-amplified, and subjected to DNA sequence analysis. Comparison the nucleotide sequence with GenBankTM/EMBL/DDBJ DNA data bases revealed 74% identity with human NFIL3/E4BP4 (4, 8) and 94% identity with mouse NFIL3/E4BP4 (9). These results suggest that the clone might be a rat homologue of NFIL3/E4BP4. To obtain the full-length cDNA of rat NFIL3/E4BP4, we used polymerase chain reaction. The 3'-half of the full-length cDNA was obtained by the 3'-RACE technique. Because we could not obtain any of the 5'-half of the cDNA using RACE, we designed a degenerate primer from the mouse NFIL3/E4BP4 sequence (clone IMAGE: 1331717) to clone the 5'-half. DNA sequencing of several subcloned PCR-generated cDNAs revealed a long open reading frame commencing with an ATG codon 127 base pairs from the 5' end of the cDNA sequence (Fig. 1). This ATG presumably represents the initiation codon, since a TGA stop codon is positioned 69 base pairs upstream of this triplet in the cDNA sequence. The open reading frame terminated at a TAA stop codon and was followed by 315 base pairs of 3'-untranslated region, including a canonical AATAAA polyadenylation signal. The molecular mass of the rat NFIL3/E4BP4 was calculated to be 50.8 kDa from an open reading frame containing 462 amino acids.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 1.   Nucleotide and predicted amino acid sequences of rat NFIL3/E4BP4 cDNA (accession number AY004663). The amino acid sequence of rat NFIL3/E4BP4 is shown in the single-letter code below the nucleotide sequence. The canonical polyadenylation signal is underlined.

Comparison of the deduced amino acid sequences of rat, mouse (9), and human NFIL3/E4BP4 (4, 8) (Fig. 2) revealed that NFIL3/E4BP4 is highly conserved among these species (83% identity between rat and human and 95% identity between rat and mouse). The characteristic features of this family are a region of basic amino acids that could bind DNA (aa 79-93) (17), a region containing leucine residues repeated every seven amino acids (aa 101-122) (18), and a novel transcriptional repressor domain (aa 299-363) (19). All these characteristic regions are well conserved across rat, mouse, and human NFIL3/E4BP4.


View larger version (80K):
[in this window]
[in a new window]
 
Fig. 2.   Comparison of the deduced amino acid sequences of rat, mouse, and human NFIL3/E4BP4. The asterisks indicate amino acid residues that are identical in all four sequences. The basic amino acid regions are underlined and the leucine repeat regions are shown in italics.

Tissue Distribution of Rat NFIL3/E4BP4 mRNA-- Northern hybridization was performed to analyze the tissue distribution of rat NFIL3/E4BP4 (Fig. 3). A 2.5-kilobase transcript could be detected in all tissues except the pancreas. Modest expression was seen in heart, lung, and skeletal muscle. Strongest expression was seen in liver, although human E4BP4 is expressed very little in the liver (7). The blot was subsequently reprobed with a radiolabeled rat beta -actin cDNA to ensure equal loading.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 3.   Tissue distribution of rat NFIL3/E4BP4. Two µg/lane of poly(A)+ RNA, prepared from the indicated rat tissues, were analyzed by Northern blotting using probes derived from cDNA for rat NFIL3/E4BP4 (upper panel) or rat beta -actin (lower panel).

Induction of NFIL3/E4BP4 mRNA by TG Treatment-- Real-time RT-PCR analysis was then performed to confirm the differential display results indicating that rat NFIL3/E4BP4 was a TG-inducible gene. As shown in Fig. 4A, treatment with TG resulted in a marked increase in rat NFIL3/E4BP4 mRNA levels. An elevation in NFIL3/E4BP4 mRNA levels was apparent within 3 h, peaked at 6 h of treatment (20-fold) and expression returned to almost basal levels by 12 h.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of thapsigargin on NFIL3/E4BP4 mRNA levels in A7r5 cells. A, time-dependent effects of thapsigargin on NFIL3/E4BP4 mRNA levels. Serum-starved A7r5 cells were incubated with 300 nM thapsigargin for the indicated periods of time. RNA was isolated and analyzed by real-time RT-PCR. The results are normalized for GAPDH mRNA levels and are representative of three similar experiments performed in triplicate. B, dose-dependent effects of thapsigargin on NFIL3/E4BP4 mRNA levels. Serum-starved A7r5 cells were treated with the indicated doses of thapsigargin for 3 h. RNA was isolated, and analyzed by real time RT-PCR. The results are normalized for GAPDH mRNA levels and are representative of three similar experiments performed in triplicate.

Dose dependence of NFIL3/E4BP4 mRNA induction by TG was also examined. The induction was increased from 1 to 30 nM with almost no further increases at higher concentrations (Fig. 4B).

TG-induced Expression of NFIL3/E4BP4 mRNA Is Dependent on Elevation of Intracellular Ca2+-- TG induces both elevations of intracellular Ca2+ concentration (2) and an endoplasmic reticulum (ER) stress response (20). We therefore tested whether a range of different stress-inducing conditions induced NFIL3/E4BP4. RASMC were exposed to one or the other of the following for a period of 3 h: 300 nM TG, 100 nM calcium ionophore A23187, or 5 µg/ml tunicamycin, an inhibitor of N-linked glycosylation. After treatment, RNA was isolated from drug-treated cells and real time RT-PCR analysis was performed to measure rat NFIL3/E4BP4 mRNA levels. NFIL3/E4BP4 mRNA was induced by TG (12-fold) and A23187 (10-fold). Tunicamycin also induced the expression of NFIL3/E4BP4 mRNA (2.8-fold), but the induction was much less than by TG and A23187 (Fig. 5A). Both TG and A23187 deplete the ER of stored Ca2+ and cause an influx of Ca2+ into the cells leading to a sustained rise in cytosolic Ca2+ concentration (1). The depletion of stored Ca2+ in ER by TG and A23187 also induced the ER stress response (20, 21). On the other hand, tunicamycin inhibits correct folding and assembly of glycoproteins within the ER and thus also activates the ER stress responses (20). These results suggest that induction of NFIL3/E4BP4 may occur predominantly as a result of elevation of the cytosolic Ca2+ concentration.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of NFIL3/E4BP4 mRNA by thapsigargin is dependent on elevation of [Ca2+]i. A, serum-starved A7r5 cells were treated with 300 nM thapsigargin, 100 nM A23187, or 5 µg/ml tunicamycin for 3 h. RNA was isolated and analyzed by real-time RT-PCR. The results are normalized for GAPDH mRNA levels and are representative of three similar experiments performed in triplicate. B, serum-starved A7r5 cells were treated with 300 nM thapsigargin with or without pretreatment with 2 mM EGTA or 10 µM BAPTA-AM for 6 h after which total RNA was extracted and analyzed for NFIL3/E4BP4 mRNA expression by real-time RT-PCR. The results are normalized for GAPDH mRNA levels and are representative of three similar experiments performed in triplicate.

To further support a role for elevation of cytosolic Ca2+ concentration mediating gene induction by TG, we next examined whether blocking the increase in cytosolic Ca2+ concentration could prevent expression of the NFIL3/E4BP4 mRNA. As shown in Fig. 5B, pretreatment of A7r5 cells with the extracellular Ca2+ chelating agent EGTA resulted in significant inhibition of TG-induced expression of NFIL3/E4BP4. Almost complete inhibition was observed when A7r5 cells were treated with 10 µM BAPTA-AM, a cell permeable Ca2+ chelating agent (Fig. 5B). These results suggest that increased cytosolic Ca2+ concentration is necessary to induce NFIL3/E4BP4 gene expression by TG.

Effects of inhibitors of Ca2+/Calmodulin-dependent Protein Phosphatase and Protein Kinases on the Induction of NFIL3/E4BP4 mRNA by TG-- Because increased cytosolic Ca2+ concentration is necessary to induce NFIL3/E4BP4 gene expression by TG, we investigated the effects of Ca2+/calmodulin-dependent protein phosphatase and protein kinases on NFIL3/E4BP4 expression. Cyclosporin A (CsA) and FK506, in complex with their immunophilin receptors, specifically inhibit the Ca2+/CaM-dependent protein phosphatase, PP2B, also known as calcineurin (22). These two inhibitors were investigated along with KN-93, an inhibitor of CaM kinase II (23) (Fig. 6). In the absence of TG, CsA, FK506, or KN-93 did not significantly influence NFIL3/E4BP4 mRNA levels. In the presence of TG, both CsA and FK506 significantly inhibited the increase in NFIL3/E4BP4. Moreover, KN-93 markedly reduced the increase in NFIL3/E4BP4 mRNA by TG. In contrast, KN-92, an inactive analog of KN-93, displayed much less inhibition than KN-93. These results suggest that the calcium dependent activation of NFIL3/E4BP4 gene expression might be mediated by calcineurin and CaM kinase.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of CsA, FK506, and KN-93 on the induction of NFIL3/E4BP4 mRNA by thapsigargin. Serum-starved A7r5 cells were treated with the 30 nM thapsigargin for 3 h with or without pretreatment of 1 µM CsA, 1 µM FK506, 1 µM KN-93, or 1 µM KN-92. RNA was isolated and analyzed by real-time RT-PCR. The results are normalized for GAPDH mRNA levels and are representative of three similar experiments performed in triplicate.

TG-induced Expression of NFIL3/E4BP4 Is Transcriptional-- Next, we explored the effect of the RNA synthesis inhibitor actinomycin D on the induction of NFIL3/E4BP4 mRNA levels by TG. A7r5 cells were treated with TG for 3 h, with or without pretreatment with actinomycin D. RNA was isolated, and NFIL3/E4BP4 mRNA levels were analyzed by real-time RT-PCR. Pretreatment with actinomycin D completely prevented the induction of NFIL3/E4BP4 mRNA by TG (Fig. 7). Thus, the increase in NFIL3/E4BP4 mRNA expression after TG addition is due, at least in part, to transcriptional activation of the NFIL3/E4BP4 gene.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of actinomycin D or cycloheximide on NFIL3/E4BP4 mRNA induction by thapsigargin. Serum starved primary A7r5 cells were either left untreated or treated with 300 nM thapsigargin for 3 h with or without pretreatment with actinomycin D or cycloheximide. Total RNA was extracted and analyzed for NFIL3/E4BP4 expression by real-time RT-PCR. The results are normalized for GAPDH mRNA levels and are representative of three similar experiments performed in triplicate.

We next used the protein synthesis inhibitor cycloheximide to determine whether TG-induced expression of NFIL3/E4BP4 mRNA was dependent on de novo protein synthesis. As shown in Fig. 7, A7r5 cells were either left untreated or treated with TG for 3 h with or without pretreatment of cycloheximide. The pretreatment of cycloheximide to TG-stimulated cells did not significantly prevent NFIL3/E4BP4 gene induction (Fig. 7). These results indicate that the induction of NFIL3/E4BP4 mRNA by TG does not require de novo protein synthesis for transcriptional activation.

TG Regulates NFIL3/E4BP4 Gene Expression by Mechanisms Involving Calcineurin-- The immunosuppressive drugs CsA and FK506 target the phosphatase activity of calcineurin. But it has also been reported that CsA and FK506 could target other proteins (e.g. JNK (24) and p38(25)). To further verify that calcineurin is involved in TG-induced expression of NFIL3/E4BP4 mRNA, we transfected dominant negative calcineurin (12) into A7r5 cells. Calcineurin dephosphorylates NFAT proteins and induces their translocation from the cytoplasm into the nucleus. The dominant negative calcineurin is exclusively cytoplasmic and interferes with NFAT translocation (12). As shown in Fig. 8, the dominant negative calcineurin (H101Q/H290Q) caused inhibition of TG-induced expression of NFIL3/E4BP4 mRNA compared with the control. These data indicate that calcineurin activity is required for the induction of NFIL3/E4BP4 mRNA expression by TG.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   A dominant negative form of calcineurin A2 (CNA2) blocks the induction of NFIL3/E4BP4 mRNA by thapsigargin. A7r5 cells were transiently transfected with the control expression vector pcD, or the dominant negative form of calcineurin pcD-CNA2(H101Q/H290Q), or its wild type pcD-CNA2. Transfection efficiency was controlled by co-transfection of the pcD-Luc expression vector. 48 h after transfection, cells were treated with or without 30 nM thapsigargin for 3 h and assayed for NFIL3/E4BP4 mRNA levels by real-time RT-PCR. The results are normalized for luciferase mRNA levels and are representative of two similar experiments performed in triplicate.

TG Regulates NFIL3/E4BP4 Gene Expression by Mechanisms Involving NFAT-- Next, the involvement of NFAT in the regulation of NFIL3/E4BP4 expression by TG was analyzed by using dominant negative NFAT (dnNFAT) (13). The dnNFAT selectively inhibited NFAT transcription activity by interfering with the activation-induced nuclear import of NFAT through the consensus sequence PxIxIT (13, 26). Interfering with the docking of calcineurin at the PxIxIT sequence impairs NFAT activation and NFAT-dependent reporter gene expression (13, 27). As shown in Fig. 9, the induction of NFIL3/E4BP4 mRNA by TG was markedly reduced in cells transfected dnNFAT (PxIxIT) although significantly less so with the mutated construct (AxIxIA). This inhibitory effect was similar to the case of the inhibition of IL-2 production by the dnNFAT (13). These data indicate that NFAT transcription activity is required for NFIL3/E4BP4 gene expression induced by TG.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 9.   A dominant negative form of NFAT blocks the induction of NFIL3/E4BP4 mRNA by thapsigargin. A7r5 cells were transiently transfected with the control expression vector pcD, or the dominant negative form of NFAT pcD-NFAT3 (PxIxIT), or its mutant form pcD-NFAT3 (AxIxIA). Transfection efficiency was controlled by co-transfection of the pcD-Luc expression vector. 48 h after transfection, cells were treated with or without 30 nM thapsigargin for 3 h and assayed for NFIL3/E4BP4 mRNA levels by real-time RT-PCR. The results are normalized for luciferase mRNA levels and are representative of two similar experiments performed in triplicate.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

This study has demonstrated that the expression of NFIL3/E4BP4 mRNA is induced by calcium signaling pathways.

The endoplasmic reticulum calcium-ATPase inhibitor TG depletes Ca2+ from internal stores, leading to Ca2+ influx and thus, to a sustained increase in [Ca2+]i (1). TG also induces an ER stress response (20). We demonstrated that chelation of extracellular and intracellular Ca2+ by EGTA and BAPTA-AM, respectively, suppressed the induction of NFIL3/E4BP4 mRNA by TG. We also demonstrated that the induction of NFIL3/E4BP4 mRNA by tunicamycin, which induces an ER stress response (20) without disturbing Ca2+ homeostasis, was less than with TG or A23187. These results suggest that an increase in [Ca2+]i is critically involved in NFIL3/E4BP4 mRNA induction by TG.

Fluxes in the amount of intracellular Ca2+ are important determinants of gene expression (1). Of the many types of Ca2+-binding proteins, calmodulin (CaM) is of major importance in vascular smooth muscle cell function. Ca2+/CaM regulates functional proteins such as calcineurin (28) and CaM kinase (29) that play important roles in gene expression in vascular smooth muscle cells. To evaluate the relative regulatory roles of calcineurin and CaM kinase, we tested the effect of inhibitors of calcineurin and CaM kinase on TG-induced NFIL3/E4BP4 mRNA expression. We have demonstrated that both CsA and FK506 inhibited the induction of NFIL3/E4BP4 mRNA. The induction of NFIL3/E4BP4 mRNA by TG was also inhibited by KN-93. These results indicate that TG induces the NFIL3/E4BP4 gene expression by calcineurin and CaM kinase-dependent mechanisms.

To further verify that TG involves calcineurin in the induction of NFIL3/E4BP4 mRNA, we transfected dominant negative calcineurin into A7r5 cells. Expression of dominant negative calcineurin strongly suppressed the induction of NFIL3/E4BP4 mRNA by TG. All of these results strongly suggest that calcineurin plays a critical role in the selective induction of NFIL3/E4BP4 mRNA by TG. Calcineurin regulates immune response genes through dephosphorylation of NFAT (28). Following dephosphorylation, NFAT is translocated into the nucleus where it binds either directly to DNA or in a complex with members of the bZIP transcription factors family such as AP-1 (30) and subsequently activates gene transcription. NFAT proteins are present in diverse cell types including vascular smooth muscle cells (31).

We tested the involvement of NFAT in NFIL3/E4BP4 mRNA expression by using the dnNFAT molecule. Inhibition of NFAT-mediated transcription by the dnNFAT resulted in significant suppression of the induction of NFIL3/E4BP4 mRNA by TG. These data indicate that NFAT is required for the expression of NFIL3/E4BP4 gene by TG. The NFAT family has a rel-type DNA-binding domain which lacks sequences in NFkappa B p50 that interact with DNA (28). In addition, a critical arginine involved in DNA binding by NFkappa B is substituted with a histidine in NFAT family members (28). NFAT family members have evolved to interact weakly with DNA and to require a partner for high-affinity DNA binding at most sites (28). Complexes induced through other signaling pathways such as AP-1 (30, 32) or cell type-specific proteins such as MEF2 (33-35), GATA2 (36), GATA4 (37), or others (38, 39) can provide the partner. Although the human NFIL3/E4BP4 gene is mapped to 9q22 (40), the complete genome sequences of human, mouse, and rat NFIL3/E4BP4 are currently unknown. Homo sapiens chromosome 9 clone RP11-440G5 (GenBankTM accession number AL353764) appears to contain the human NFIL3/E4BP4 gene. The structure of the NFIL3/E4BP4 gene and the exact mechanisms by which NFAT activates the expression of NFIL3/E4BP4 are still to be determined.

KN-93 prevents the activation of CaM kinase II by interacting with the calmodulin-binding domain of the kinase (23). As shown in Fig. 6, 1 µM KN-93 markedly reduced the TG-induced NFIL3/E4BP4 expression, whereas 1 µM KN-92, an inactive analog of KN-93, displayed much less inhibitory effects than KN-93. These results suggest that CaM kinase signaling is involved in the TG-dependent NFIL3/E4BP4 induction. Although KN-93 show a high degree of selectivity for CaM kinase, other nonspecific effects on cellular function cannot be ruled out. For example, KN-93 suppressed voltage-dependent K+ channels in vascular myocytes (41). It is reported that inhibition of voltage-dependent K+ channels in T lymphocyte resulted in suppression of calcium signaling and NFAT-driven gene expression (42). To obtain more direct evidence for the involvement of CaM kinase signaling, we transfected a CaM kinase II isoform to A7r5 cells. Expression of the CaM kinase II isoform in A7r5 cells resulted in enhanced elevation of TG-induced NFIL3/E4BP4 expression, relative to empty vector control expression (data not shown). These data suggest that CaM kinase signaling is involved in the TG-dependent NFIL3/E4BP4 induction. Additional studies are required to define that the CaM kinase responsible for TG-induced NFIL3/E4BP4 expression is CaM kinase II or other CaM kinases.

CaM kinase II has been reported to mediate the activation of c-Fos (1), which can form heterodimeric complexes with c-Jun (e.g. AP-1). It is possible that calcineurin and CaM kinase II activate NFAT and AP-1 expression, respectively, and that NFAT and AP-1 stimulate the NFIL3/E4BP4 mRNA expression in concert with each other. Another possibility is that calcineurin and CaM kinase signaling pathways may act in parallel to preferentially target NFAT and MEF2, respectively, because CaM kinase I (35) and CaM kinase IV (33-35) can activate the MEF2 transcription factors. The CaM kinases can also activate cAMP response element-binding protein and serum response element-binding protein (1). Therefore, it is possible that these transcription factors may mediate some of the effects of TG on the induction of NFIL3/E4BP4 independently of NFAT. CaM kinase II can also mediate the activation of the ERK pathway following stimulation of calcium influx by ionomycin in vascular smooth muscle cells (43). Thus, CaM kinase II may serve to regulate NFIL3/E4BP4 expression via ERK1/ERK2. In fact, we found that TG-dependent NFIL3/E4BP4 induction was suppressed by pretreatment with 10 µM PD98059, a specific inhibitor of MEK1/2 (data not shown). In Baf-3 cells, the expression of NFIL3/E4BP4 was regulated by oncogenic Ras mutant proteins through both the Raf-MAP kinase and phosphatidylinositol 3-kinase pathways (10). The effect of the MAP kinase pathway in TG-induced NFIL3/E4BP4 mRNA expression in RASMC remains to be studied.

In the mouse pro-B cell lines Baf-3 and FL5.12, expression of NFIL3/E4BP4 was regulated by IL-3 requiring de novo protein synthesis (9). We demonstrated that the protein synthesis inhibitor cycloheximide did not significantly suppress the induction of NFIL3/E4BP4 by TG, suggesting that the mechanism of which IL-3 induces NFIL3 gene expression in Baf-3 and FL5.12 is different from the mechanism by which TG induces the expression of NFIL3/E4BP4 mRNA in RASMC. In the human T cell lines MLA144 and HUT78, NFIL3/E4BP4 mRNA levels increased after PMA stimulation, although the amount of NFIL3/E4BP4 mRNA did not change following PMA stimulation in S-LB-1 T cells (8). We found that PMA did not induce the expression of NFIL3/E4BP4 mRNA in RASMC (data not shown). These results suggest that there are some differences in the cellular proteins reacting after PMA stimulation between these cell lines.

It is very important to know the physiological significance of NFIL3/E4BP4 induction. It is known that NFIL3/E4BP4 functions as an anti-apoptotic transcription factor in murine IL-3-dependent Pro-B lymphocytes including Baf-3 and FL5.12 cells (9, 10). In the absence of IL-3, enforced expression of the human NFIL3/E4BP4 promoted the survival but not the growth of IL-3-dependent pro-B cells, indicating that induction of NFIL3/E4BP4 is one of the mechanisms through which IL-3 suppresses apoptosis (9). The downstream factors through which NFIL3/E4BP4 delays apoptosis in IL-3-deprived Baf-3 cells have as yet not been identified. One possibility is that NFIL3/E4BP4 induces the expression of cytokine in Baf-3 cells and blocks apoptosis through an autocrine mechanism, because this transcription factor has been reported to transactivate the IL-3 promoter in T cells. We found that rat IL-3beta mRNA (44) was induced by TG in RASMC (data not shown). Although NFAT can directly activate the human GM-CSF/IL-3 promoter (28, 45) and IL-3 mRNA is stabilized following stimulation of calcium influx by ionomycin (46), it is also possible that TG might activate IL-3beta expression through the induction of NFIL3/E4BP4 expression in RASMC. The induction of NFIL3/E4BP4 by calcium signaling might have some critical functions in apoptosis in vascular smooth muscle cells.

    ACKNOWLEDGEMENTS

We thank Hai An Zheng for assistance with experiments and the members of the Department of Molecular and Cellular Pharmacology, Mie University School of Medicine, for their continual help and support.

    FOOTNOTES

* This work was supported in part by grants-in-aid for Scientific Research on Priority Areas, Scientific Research (A) and (B), International Scientific Research (Joint Research) and Exploratory Research from the Ministry of Education, Science, Sports and Culture, a grant from the Pediatric Diseases from the Ministry of Health and Welfare, the Program for Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research, Japan, grants for Research Projects on Muscle Regulation and on Cerebral Vasospasm from Mie University School of Medicine, and a Grant-in-Aid 1996 from the Mie Medical Research Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) data of rat NFIL3/E4BP4 reported in this paper has been submitted to DDBJ, EMBL, and NCBI data bases with the accession number(s) AY004663.

Dagger To whom correspondence should be addressed: Dept. of Molecular and Cellular Pharmacology, Mie University School of Medicine, Edobashi, Tsu, Mie 514-8507, Japan. Tel.: 81-59-232-5006; Fax: 81-59-232-1765; E-mail: tanaka@doc.medic.mie-u.ac.jp.

Published, JBC Papers in Press, March 21, 2001, DOI 10.1074/jbc.M010332200

    ABBREVIATIONS

The abbreviations used are: TG, thapsigargin; NFAT, nuclear factor of activated T cells; RASMC, rat aortic smooth muscle cells; PMA, phorbol 12-myristate 13-acetate; RACE, rapid amplification of cDNA ends; RT-PCR, reverse transcriptase-polymerase chain reaction; aa, amino acid(s); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ER, endoplasmic reticulum; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl; CsA, cyclosporin A; dnNFAT, dominant-negative nuclear factor of activated T cells; ERK, extracellular regulated kinase; NFIL-3, nuclear factor regulated by interleukin 3; E4BP4, adenovirus E4 binding protein; CaM, calmodulin; CaM kinase, calcium/calmodulin-dependent protein kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Rosen, L. B., Ginty, D. D., and Greenberg, M. E. (1995) Adv. Second Messenger Phosphoprotein Res. 30, 225-253[Medline] [Order article via Infotrieve]
2. Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466-2470[Abstract]
3. Ito, T., Kito, K., Adati, N., Mitsui, Y., Hagiwara, H., and Sakaki, Y. (1994) FEBS Lett. 351, 231-236[CrossRef][Medline] [Order article via Infotrieve]
4. Cowell, I. G., Skinner, A., and Hurst, H. C. (1992) Mol. Cell. Biol. 12, 3070-3077[Abstract]
5. Chen, W. J., Lewis, K. S., Chandra, G., Cogswell, J. P., Stinnett, S. W., Kadwell, S. H., and Gray, J. G. (1995) Biochim. Biophys. Acta 1264, 388-396[Medline] [Order article via Infotrieve]
6. Wallace, A. D., Wheeler, T. T., and Young, D. A. (1997) Biochem. Biophys. Res. Commun. 232, 403-406[CrossRef][Medline] [Order article via Infotrieve]
7. Lai, C. K., and Ting, L. P. (1999) J. Virol. 73, 3197-3209[Abstract/Free Full Text]
8. Zhang, W., Zhang, J., Kornuc, M., Kwan, K., Frank, R., and Nimer, S. D. (1995) Mol. Cell. Biol. 15, 6055-6063[Abstract]
9. Ikushima, S., Inukai, T., Inaba, T., Nimer, S. D., Cleveland, J. L., and Look, A. T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2609-2614[Abstract/Free Full Text]
10. Kuribara, R., Kinoshita, T., Miyajima, A., Shinjyo, T., Yoshihara, T., Inukai, T., Ozawa, K., Look, A. T., and Inaba, T. (1999) Mol. Cell. Biol. 19, 2754-2762[Abstract/Free Full Text]
11. Frohman, M. A. (1993) Methods Enzymol. 218, 340-356[Medline] [Order article via Infotrieve]
12. Shibasaki, F., Price, E. R., Milan, D., and McKeon, F. (1996) Nature 382, 370-373[CrossRef][Medline] [Order article via Infotrieve]
13. Chow, C. W., Rincon, M., and Davis, R. J. (1999) Mol. Cell. Biol. 19, 2300-2307[Abstract/Free Full Text]
14. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
15. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. (1996) Genome Res. 6, 986-994[Abstract]
16. Gibson, U. E., Heid, C. A., and Williams, P. M. (1996) Genome Res. 6, 995-1001[Abstract]
17. Vinson, C. R., Sigler, P. B., and McKnight, S. L. (1989) Science 246, 911-916[Medline] [Order article via Infotrieve]
18. Landschulz, W. H., Johnson, P. F., and McKnight, S. L. (1988) Science 240, 1759-1764[Medline] [Order article via Infotrieve]
19. Cowell, I. G., and Hurst, H. C. (1994) Nucleic Acids Res. 22, 59-65[Abstract]
20. Haze, K., Yoshida, H., Yanagi, H., Yura, T., and Mori, K. (1999) Mol. Biol. Cell 10, 3787-3799[Abstract/Free Full Text]
21. Kokame, K., Agarwala, K. L., Kato, H., and Miyata, T. (2000) J. Biol. Chem. 275, 32846-32853[Abstract/Free Full Text]
22. Liu, J., Farmer, J. D., Jr., Lane, W. S., Friedman, J., Weissman, I., and Schreiber, S. L. (1991) Cell 66, 807-815[Medline] [Order article via Infotrieve]
23. Sumi, M., Kiuchi, K., Ishikawa, T., Ishii, A., Hagiwara, M., Nagatsu, T., and Hidaka, H. (1991) Biochem. Biophys. Res. Commun. 181, 968-975[Medline] [Order article via Infotrieve]
24. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., and Ben-Neriah, Y. (1994) Cell 77, 727-736[Medline] [Order article via Infotrieve]
25. Matsuda, S., Moriguchi, T., Koyasu, S., and Nishida, E. (1998) J. Biol. Chem. 273, 12378-12382[Abstract/Free Full Text]
26. Garcia-Cozar, F. J., Okamura, H., Aramburu, J. F., Shaw, K. T. Y., Pelletier, L., Showalter, R., Villafranca, E., and Rao, A. (1998) J. Biol. Chem. 273, 23877-23883[Abstract/Free Full Text]
27. Aramburu, J., Yaffe, M. B., Lopez-Rodriguez, C., Cantley, L. C., Hogan, P. G., and Rao, A. (1999) Science 285, 2129-2133[Abstract/Free Full Text]
28. Crabtree, G. R. (1999) Cell 96, 611-614[Medline] [Order article via Infotrieve]
29. Means, A. R. (2000) Mol. Endocrinol. 14, 4-13[Free Full Text]
30. Jain, J., McCaffrey, P. G., Miner, Z., Kerppola, T. K., Lambert, J. N., Verdine, G. L., Curran, T., and Rao, A. (1993) Nature 365, 352-355[CrossRef][Medline] [Order article via Infotrieve]
31. Boss, V., Abbott, K. L., Wang, X. F., Pavlath, G. K., and Murphy, T. J. (1998) J. Biol. Chem. 273, 19664-19671[Abstract/Free Full Text]
32. Macian, F., Garcia-Rodriguez, C., and Rao, A. (2000) EMBO J. 19, 4783-4795[Abstract/Free Full Text]
33. Blaeser, F., Ho, N., Prywes, R., and Chatila, T. A. (2000) J. Biol. Chem. 275, 197-209[Abstract/Free Full Text]
34. Wu, H., Naya, F. J., McKinsey, T. A., Mercer, B., Shelton, J. M., Chin, E. R., Simard, A. R., Michel, R. N., Bassel-Duby, R., Olson, E. N., and Williams, R. S. (2000) EMBO J. 19, 1963-1973[Abstract/Free Full Text]
35. Passier, R., Zeng, H., Frey, N., Naya, F. J., Nicol, R. L., McKinsey, T. A., Overbeek, P., Richardson, J. A., Grant, S. R., and Olson, E. N. (2000) J. Clin. Invest. 105, 1395-1406[Abstract/Free Full Text]
36. Musaro, A., McCullagh, K. J., Naya, F. J., Olson, E. N., and Rosenthal, N. (1999) Nature 400, 581-585[CrossRef][Medline] [Order article via Infotrieve]
37. Molkentin, J. D., Lu, J. R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., and Olson, E. N. (1998) Cell 93, 215-228[Medline] [Order article via Infotrieve]
38. Tsai, E. Y., Jain, J., Pesavento, P. A., Rao, A., and Goldfeld, A. E. (1996) Mol. Cell. Biol. 16, 459-467[Abstract]
39. Falvo, J. V., Uglialoro, A. M., Brinkman, B. M., Merika, M., Parekh, B. S., Tsai, E. Y., King, H. C., Morielli, A. D., Peralta, E. G., Maniatis, T., Thanos, D., and Goldfeld, A. E. (2000) Mol. Cell. Biol. 20, 2239-2247[Abstract/Free Full Text]
40. Hulme, D. J., Blair, I. P., Dawkins, J. L., and Nicholson, G. A. (2000) Hum. Genet. 106, 594-596[CrossRef][Medline] [Order article via Infotrieve]
41. Ledoux, J., Chartier, D., and Leblanc, N. (1999) J. Pharmacol. Exp. Ther. 290, 1165-1174[Abstract/Free Full Text]
42. Ehring, G. R., Kerschbaum, H. H., Eder, C., Neben, A. L., Fanger, C. M., Khoury, R. M., Negulescu, P. A., and Cahalan, M. D. (1998) J. Exp. Med. 188, 1593-1602[Abstract/Free Full Text]
43. Abraham, S. T., Benscoter, H. A., Schworer, C. M., and Singer, H. A. (1997) Circ. Res. 81, 575-584[Abstract/Free Full Text]
44. del, C., E. M., van Someren, G. D., van der Velde, I., van Bekkum, D. W., Valerio, D., Noteboom, J. L., and Bout, A. (1998) Gene 211, 151-158[CrossRef][Medline] [Order article via Infotrieve]
45. Duncliffe, K. N., Bert, A. G., Vadas, M. A., and Cockerill, P. N. (1997) Immunity 6, 175-185[Medline] [Order article via Infotrieve]
46. Stoecklin, G., Hahn, S., and Moroni, C. (1994) J. Biol. Chem. 269, 28591-28597[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.